A tech-bio startup leveraging antibody big data and AI to tackle the challenges of drug discovery: identifying unresolved diseases and undiscovered target molecules. Breaking through the barriers of bio-data to pioneer new therapies.
[画像: https://prtimes.jp/i/104790/7/resize/d104790-7-89c8694c4d468e84072e-1.png ] 公開したデータセットをダウンロードできるWebサイト（https://avida-hil6.cognanous.com/） [表: https://prtimes.jp/d...
本事業は、8月9日の大阪府知事定例記者会見において発表された通り、令和５年度創薬シーズ研究開発費補助金として採択されました。事業名称は「新規がんマーカーを標的とするVHH創薬の高速プラットフォーム戦略（...
[画像1: https://prtimes.jp/i/104790/5/resize/d104790-5-7853acf9474c8fae17f8-3.jpg ] Fig. 1. TNBC89バイオマーカー(赤) が、エストロゲン受容体(緑)の発現が低い浸潤性乳管癌を染めている。 [画像2: http...
[画像: https://prtimes.jp/i/104790/2/resize/d104790-2-1151b0e11903c76a6885-0.jpg ] 京都のバイオラボでのバイオマンとエンジニアの作戦会議風景   1. 背景 新型コロナウイルス感染症（COVID-1...
Based on advanced AI technology developed at Kyoto University, we provide services that visualize and predict physical, mental, and psychological states. At its core are two technologies: “Physical and Mental State Prediction Technology through Environmental Factor Analysis” developed by Associate Professor Tsutomu Nishimura of Kyoto University Hospital, and “Psychological State Estimation Technology using Natural Language Processing AI” developed by Assistant Professor Takuya Mori and Associate Professor Nishimura. We deploy AI solutions that estimate loneliness and happiness from text information, enable early detection of risks for school refusal and social withdrawal, and propose optimal support tailored to individual circumstances.
A Kyoto University-spinoff startup providing solutions based on generative AI technology, including data augmentation for manufacturing, drawing recognition, and AI call centers. Supporting operational innovation and digital transformation across diverse industries.
A startup that automates literature search, analysis, and organization through proprietary semantic search technology and AI workflows. It dramatically boosts researcher productivity and addresses information overload and inefficiency in academic and corporate R&D.
A startup developing proprietary technology that utilizes fish-derived gut bacteria to enhance aquaculture fish growth and strengthen immunity. Centered on aquaculture support through bacterial cocktails, it also tackles land-based aquaculture and branded fish production.
